TCF12

Across TCGA pan-cancer cohorts, TCF12 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TCF12 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TCF12 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TCF12 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and CCRCC are the cancer types where TCF12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.871	0.467	.012	8	view →
GBM	OS	Tertile	All	0.594	0.313	.009	7	view →
CCRCC	OS	Quartile	III,IV	1.000	0.801	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TCF12–LUAD (OS)

Open the LUAD breakdown →